Sie sind hier: Startseite Termine Market Access of Orphan Drugs
Um unsere Webseite für Sie optimal zu gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zu Cookies erhalten Sie in unserer Datenschutzerklärung.

Market Access of Orphan Drugs

05.11.2021 13:41
Evidence generation, value proposition and the HTA - the latest insights with regard to Orphan Drugs



von 09:00 bis 17:00



Termin übernehmen

Aims and objectives:

The orphan drug sector is about to change. EU orphan drug and paediatric legislation is under review and the EU HTA is fast approaching - it is time for a thorough update on regulatory and HTA issues.

This course provides the latest on marketing authorisation and market access, as well as practical tips for evidence generation and value creation.



- Evidence generation with small patient groups
- Evaluation of the orphan and paediatric legislation
- Orphan drugs in the German AMNOG procedure
- Value proposition from a health insurance perspective
- Value creation process for a launch in the EU4 and the UK


Who should attend?

This course addresses the needs of all who are involved in regulatory affairs or market access with small patient groups or orphan drug status. It is also recommended for those who address medical affairs and clinical issues related to orphan drugs.

Weitere Informationen über diesen Termin…